Ultragenyx

#Antisense Oligonucleotides (ASOs) #Orphan drugs #Phase III trial #Rare disease #Ultragenyx

Ultragenyx’s ASO for Angelman Syndrome fails at Phase III

Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score.  The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More

#News

#FDA #Gene therapy #Rare disease #Ultragenyx

FDA approves gene therapy for glycogen storage disease type Ia

The US Food and Drug Administration (FDA) granted accelerated approval for Ultragenyx Pharmaceutical’s Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and paediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).  Dr Eric Crombez, Chief Medical Officer at Ultragenyx, commented: “As our first gene therapy… Read More

#News #Regulatory

FDA
#AAV #FDA #Gene therapy #Manufacturing #Rare disease #Ultragenyx

FDA raises manufacturing concerns for Ultragenyx gene therapy

The US Food and Drug Administration (FDA) has decided not to recommend Ultragenyx Pharmaceutical’s UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).   In its complete response letter (CRL), the FDA requested that the company provide additional information and improvements related to… Read More

#News #Regulatory #Trending News